EXOZ EXOZYMES INC.

CIK 0002010788 20 ready 8-Ks latest June 25, 2026, 7:36 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 20

Latest filing July 1, 2026, 4:30 PM ET

Top materiality 0.75

Event mix other_material ×15 · other ×2 · leadership ×2

Sentiment 5 pos · 0 neg · 15 neu

Executive change recent →

Recent 8-K filings for EXOZ

Highest-materiality recent filing

Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC

November 18, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
Concurrent private placement issued 93,750 warrants at $0.125, exercisable at $8.00 for 5 years.

Read filing →

June 25, 2026, 7:36 PM ET regulatory materiality 0.60 positive item 7.01 item 9.01

eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery

NIH NIGMS Phase IIB SBIR grant of $2,028,518 to support development of rare cannabinoids and engineered analogs.
June 17, 2026, 5:11 PM ET other material materiality 0.65 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements ×2

eXoZymes closes public offering raising $5.95M; over-allotment partially exercised

Gross proceeds of ~$5.95M from 330,575 units (2 shares + 1 warrant per unit) at $18.00/unit.
June 8, 2026, 2:19 PM ET other material materiality 0.65 neutral item 1.01 item 7.01 item 9.01 ◈ Material Agreements

eXoZymes prices $5.33M offering of common stock and warrants at $18/unit

Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.
February 5, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

eXoZymes reports 535g NCT pilot run at 99% conversion, 90% yield, 99.6% purity

Achieved ~99% reaction conversion, 90% isolated yield, and 535 g of NCT at 99.6% pharma-grade purity from a 100L pilot run.
June 26, 2025, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 9.01

eXoZymes to receive $3M from NSF as key partner in $9.2M cell-free biomanufacturing initiative

Selected as core industrial partner in Meta-PURE, a $9.2M NSF-funded project under CFIRE program.
November 18, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC

Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.

Executive changes

Appointed

Christopher A. Marlett

Chairman of the Board

EXOZ · EXOZYMES INC.

Effective: 2025-02-17
Filed: February 21, 2025, 6:59 PM ET

The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.

Departed

Mohammad Hayat

President and Chairman

EXOZ · EXOZYMES INC.

Effective: 2025-02-17
Filed: February 21, 2025, 6:59 PM ET

On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors (the “ Board ”) of eXoZymes Inc., a Nevada corporation (the “ Company ”), as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company.

Appointed

Edgardo Rayo

member of the Board

EXOZ · EXOZYMES INC.

Effective: 2025-02-17
Filed: February 21, 2025, 6:59 PM ET

On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.50 · Most common event other_material

5 positive 0 negative 15 neutral

source · EXOZ on sec.gov